The salvage liver transplantation (SLT) strategy was conceived for initially resectable and transplantable (R&T) hepatocellular carcinoma (HCC) patients, to try to obviate upfront liver transplantation, with the "safety net" of SLT in case of postresection recurrence. The SLT strategy is successful or curative when patients are recurrence free following primary resection alone, or after SLT for recurrence. The aim of the current study was to determine the SLT strategy's potential for cure in R&T HCC patients, and to identify predictors for its success. From 1994 to 2012, all R&T HCC patients with cirrhosis were enrolled in the SLT strategy. An intention-to-treat (ITT) analysis was used to determine this strategy's outcomes and predictors of success according to the above definition. In total, 110 patients were enrolled in the SLT strategy. Sixty-three patients (57%) had tumor recurrence after initial resection, and in 30 patients SLT could be performed (recurrence transplantability rate 5 48%). From the time of initial resection, ITT 5-year overall and disease-free survival rates were 69% and 60%, respectively. The SLT strategy was successful in 60 patients (56%), either by resection alone (36%), or by SLT for recurrence (19%). Preresection predictors of successful SLT strategy at multivariate analysis included Model for End-Stage Liver Disease (MELD) score >10, and absence of neoadjuvant transarterial chemoembolization (TACE). Additional postresection predictive factors were absence of postresection morbidity, and T-stage 1-2 at the resection specimen. Conclusion: The SLT strategy is curative in only 56% of cases. Higher MELD score at inception of the strategy and no pre-resection TACE are predictors of successful SLT strategy. (HEPATOLOGY 2018;67:204-215).
T he salvage liver transplantation (SLT) strategy consists of primary liver resection for resectable and transplantable (R&T) hepatocellular carcinoma (HCC), followed by SLT in case of transplantable tumor recurrence. (1, 2) This could help in alleviating both the graft shortage and the dropout from the transplant waiting list, which occurs in 25%-30% of cases after 12 months, mainly attributed to tumor progression. (3, 4) The aforementioned definition of the SLT strategy excludes LT "de principe" (also called preemptive) after resection based on the histopathological examination of the resection specimen, (5) resection as a bridge to liver transplantation (LT) where the tumor (transplantable or not) is resected in the waiting Abbreviations: AASLD, American Association for the Study of Liver Diseases; AFP, a-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; CT, computed tomography; DFS, disease-free survival; EASL, European Association for the Study of the Liver; HCC, hepatocellular carcinoma; IQR, interquartile range; ITT, intention-to-treat; LDLT, living donor liver transplantation; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; MRI, magnetic resonance imaging; OS, overall survival; PH, portal hypertension; PVTT, portal vein tumor thrombus; RR, relative risk; R&T, resectable and transplantable; SLT, salvage liver transplantation; TACE, transarterial chemoembolization; VH, viral hepatitis.
period after the patient has been listed for LT, (6) and the rare cases of rescue LT for postoperative irreversible liver failure following liver resection.
To date, studies in HCC patients have not focused on the likelihood of cure from the patient's perspective, in contrast to other cancers. (7) To put into this perspective, the SLT strategy is a success and "truly curative" when resection with or without subsequent SLT is not followed by postoperative death or disease recurrence after a sufficient follow-up period of conventionally 5 years. Conversely, the strategy has failed in case of: (1) postoperative death (after resection or SLT); (2) denial of listing for SLT in case of recurrence because of medical (8) or oncological reasons (9, 10) ; (3) dropout from the waiting list for SLT for any reason; and (4) tumor recurrence following SLT.
The reported actual transplantability rate of HCC recurrence following primary resection (which occurs in up to 70% of cases at 5 years (11) ) is below 50% in most series (Supporting Table S1 ( 2, 5, ). Thus, successful SLT strategy cannot be guaranteed to the patient before liver resection.
The objective of our study was to analyze the success rate of the SLT strategy from the patient's perspective on an intention-to-treat (ITT) basis. Independent predictors of a successful SLT strategy were identified among variables available before primary resection to facilitate the shared-decision process to embark on such a strategy. In addition, perioperative and histopathological factors were subsequently added to the analysis, to enable a second decisionmaking moment after resection whether to continue with this strategy (i.e., to wait for recurrence before SLT), or to change the treatment strategy for the individual patient.
Patients and Methods

STUDY POPULATION
All consecutive patients with cirrhosis who underwent liver resection for R&T HCC at our institution between 1994 and 2012 were enrolled in the SLT strategy and included in the study. Patients were identified from our prospectively maintained Human Subject Committee-approved database and retrospectively analyzed. Patients treated between 1990 and 2007 were reported previously. (13) In the current analysis, only patients with complete medical records were included, and therefore the study period started in 1994. No donor organs were obtained from executed prisoners or other institutionalized persons.
HCC patients were considered primarily resectable when fulfilling all of the following criteria: (1) absence of prohibitive comorbidities; (2) acceptable liver function (depending on the planned extent of resection); (3) planned macroscopic complete resection (R0 resection); and (4) absence of extrahepatic disease. Presence of portal hypertension (PH) was not considered a strict contraindication for resection, provided that there was no history of encephalopathy, ascites, or variceal rupture.
Patients with HCC were considered transplantable when they fulfilled all of the following criteria: (1) absence of prohibitive comorbidities; (2) age 70 years; and (3) HCC within the Milan criteria evaluated on preoperative imaging. (9) HCC patients were considered R&T when they fulfilled all of the criteria for resection and LT.
SLT was defined as LT performed in patients with HCC recurrence after a primary resection for R&T
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HCC, provided that the recurrent tumor met the Milan criteria (i.e., fulfilled our local transplantation criteria) and was the primary indication for listing for LT.
Patients who underwent SLT for HCC recurrence following primary resection for nontransplantable HCC (downstaging), (34) those who underwent LT after resection as a bridge therapy, (6) or those who underwent LT "de principe," (5) were excluded from the analysis. Patients enrolled in the SLT strategy who underwent LT for postoperative irreversible liver failure following primary resection for R&T HCC (rescue LT) were included in the ITT analysis, but excluded from other analyses because they were neither exposed to early death nor to tumor recurrence following resection.
DIAGNOSTIC WORKUP AND SURGICAL TECHNIQUES
Before 2005, HCC was diagnosed according to acknowledged criteria. (35) After 2005, diagnosis of HCC was based on the guidelines of the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL). (36, 37) Percutaneous biopsy of the tumor and nontumor parenchyma was performed whenever required. The details of surgical techniques and patient selection criteria for liver resection and LT have been described. (38) 
HISTOPATHOLOGICAL EXAMINATION
Histopathological examination of the resection and explanted specimen included the following: number, size and location of tumor nodules, presence of vascular invasion (none, macroscopic, or microscopic), presence of satellite nodules, histological tumor grade, and surgical margins in case of resection.
POSTOPERATIVE OUTCOMES AND FOLLOW-UP
Postoperative mortality and morbidity were defined as death or complications within 3 months of surgery or at any time during initial hospitalization postsurgery. Postoperative morbidity was classified according to the Dindo-Clavien classification. (39) Postoperative follow-up included liver function tests, a-fetoprotein (AFP) level, and four-phase computed tomography (CT) or magnetic resonance imaging (MRI) starting at 3 months after the operation, and then every 3 months for 2 years, and thereafter every 6 months.
STATISTICAL ANALYSIS
Patient characteristics are expressed as median with interquartile range (IQR) for continuous data and as frequency for categorical data. Differences between subgroups were compared with the chisquare test and Mann-Whitney U test, as appropriate. Univariate analysis was performed to identify factors significantly related to successful SLT strategy by using the chi-square test. To identify independent predictors of successful SLT strategy, a multivariate analysis (logistic regression) was performed, including all relevant factors with a univariate P 0.10. The analyses were performed in two ways: (1) including only preoperatively available factors and (2) including preoperative, operative, and histopathological factors.
Overall (OS) and disease-free survival (DFS) rates after initial liver resection were calculated by the Kaplan-Meier method on an ITT basis (i.e., from the date of primary liver resection for the total study population). Survival rates of patients with successful SLT strategy were compared to those in whom the SLT strategy failed by using the log-rank test. A P value 0.05 was considered statistically significant. SPSS software (version 20.0; SPSS, Inc., Chicago, IL) was used for all statistical analyses.
Results
STUDY POPULATION
Between 1994 and 2012, 356 patients with liver cirrhosis underwent liver resection for HCC ( Figure 1 ). Of these, 246 patients (69%) did not fulfill the criteria for LT at the time of liver resection, and were therefore excluded from the study. The remaining study population consisted of 110 patients considered both R&T at the time of liver resection and were enrolled in the SLT strategy. The study population and outcomes are summarized in the flow chart of Fig. 1 .
There were 89 men (81%) and 21 women (19%), with a median age of 58.5 years (IQR, 51.2-64.6; Table 1 ). Underlying chronic liver disease was attributed to viral hepatitis (VH) in 63 patients (57%) and 
PRIMARY LIVER RESECTION
In 11 patients (10%), transarterial chemoembolization (TACE) had been performed before referral to our center. Laparoscopic liver resection was performed in 54 patients (49%). Twenty-seven patients (25%) underwent a major hepatectomy (3 segments; Table  2 ). HCC was confirmed histologically in all cases (Supporting Table S2 ).
Six patients (5%) died within 90 days after liver resection (because of liver failure in 4 cases and sepsis in 2 cases). These six patients could not be listed for rescue LT because of almost simultaneous onset of multiple organ failure. The postoperative morbidity rate was 31% (34 of 110 patients; Table 2 ). Two patients (2%) needed rescue LT within 1 month postresection.
DISCREPANCY OF TRANSPLANTABILITY UPON PRERESECTION IMAGING VERSUS HISTOPATHOLOGICAL SPECIMEN ANALYSIS
Although all patients met the Milan criteria for LT upon preresection imaging, 31 patients (28%) were found to be actually outside the Milan criteria at histopathological examination of the resection specimen (11 patients because of larger tumor size, 7 because of larger tumor size and macroscopic subsegmental portal vein tumor thrombus [PVTT], 1 because of both larger tumor number and greater size, 1 had a greater tumor number and size combined with macroscopic subsegmental PVTT, and 11 had macroscopic PVTT; Supporting Table S2 ).
TUMOR RECURRENCE AFTER INITIAL LIVER RESECTION
Following liver resection, 57% of patients (63 of 110) on an ITT basis and 62% of patients (63 of 102), when excluding six postoperative deaths and two
Flow chart study population. *Patients who underwent rescue LT were only included in the intention-to-treat analysis, and excluded from the SLT strategy population. Successful SLT strategy is defined as survival without recurrence after a sufficient followup either after resection or after SLT. Failed SLT strategy is defined as postresection or post-SLT death, nontransplantable recurrence (i.e., exceeding transplantation tumor criteria or de novo medical reasons), dropout from the waiting list, or post-SLT tumor recurrence. Rescue liver transplantation is defined as LT for irreversible liver failure after liver resection.
rescue LTs, developed HCC recurrence. The median time to recurrence was 14.1 months (IQR, 6.2-29.1). Of these, 16 patients (25%) did not fulfil our local transplantation criteria (either exceeding Milan criteria in 9 cases or because of concomitant extrahepatic metastases in 7); 14 of these had died at last follow-up. The remaining 47 patients (47 of 63; 75%) with HCC recurrence who fulfilled the transplantation criteria were listed for SLT within 2 months of diagnosis of recurrence. Seventeen patients (17 of 47; 36%) 
SUCCESS OF THE SLT STRATEGY
After exclusion of the 2 cases of rescue LT, the SLT strategy could be considered successful in 60 patients (60 of 108; 56%), 39 patients (36%) who were without disease recurrence following resection alone at last follow-up and 21 (19%) without tumor recurrence following SLT. On the other hand, the SLT strategy had failed in 48 patients (48 of 108; 44%): 6 patients died posthepatectomy, 1 died post-SLT, 16 presented with nontransplantable HCC recurrence postresection, 17 dropped out from the waiting list for SLT, and 8 developed disease recurrence after SLT. Whereas 75% (47 of 63 patients) of patients with recurrence were deemed transplantable, only 48% (30 of 63 patients) could actually be transplanted.
LONG-TERM OUTCOMES
The median follow-up was 53.9 months (IQR, 24.8-92.5) after primary liver resection for the entire study population and 62.6 months (IQR, 37.6-96.1) for patients alive at last follow-up. Following primary liver resection (ITT population), 1-, 3-, and 5-year OS rates were 88%, 73%, and 69%, respectively (Fig. 2) . In the same population, 1-, 3-, and 5-year DFS rates were 81%, 63%, and 60%, respectively (Fig. 2) .
One-, 3-, and 5-year OS and DFS rates starting from the time of SLT were 93%, 89%, and 85%, and 93%, 82%, and 69%, respectively.
One-, 3-, and 5-year OS was significantly higher among patients in whom the SLT strategy was successful, compared with those in whom the SLT strategy had failed (96%, 93%, and 93% vs. 77%, 50%, and 41%; P < 0.001; Fig. 3A) . Similarly, 1-, 3-, and 5-year DFS after primary liver resection was significantly higher in patients with successful SLT strategy compared with failed SLT strategy (96%, 93%, and 93% vs. 61%, 26%, and 21%; P < 0.001; Fig. 3B ).
INDEPENDENT PREDICTORS OF SUCCESSFUL SLT STRATEGY
At multivariate analysis, two independent predictors of successful SLT strategy were identified among factors available before primary resection: MELD score >10 (relative risk [RR], 6.3; 95% confidence interval [CI], 1.5-27.1; P 5 0.01) and absence of preoperative TACE (RR, 5.9; 95% CI, 1.2-28.3; P 5 0.03; Table 3 ). After including primary liver resection and histopathological factors, multivariate analysis identified three independent predictors of successful SLT strategy: MELD score >10 (RR, 9.3; 95% CI, 1.9-45.8; P 5 0.006); no postoperative morbidity (RR, 6.1; 95% CI, 2.1-17.2; P 5 0.001); and tumor stage 1-2 on histopathology of the resected specimen (RR, 4.6; 95% CI, 1.4-15.6; P 5 0.01; Table 3 ). The influence of each preoperative predictive factor on OS and DFS is illustrated in Supporting Figs. S1 and S2. The complete univariate analyses are shown in Supporting  Tables S3 and S4 .
Discussion
The present study is one of the few evaluating the results of the SLT strategy on an ITT basis and the first using the concept of success of the strategy from the patient's perspective. In the current study, upfront R&T HCC patients enrolled in the SLT strategy were "truly cured" by this strategy in only 56% of cases, either by liver resection alone (36% of patients) or by SLT (19% of patients).
The gap between theoretical and actual transplantability following HCC recurrence in the SLT strategy is a point of constant debate. On an ITT basis, our study showed that the theoretical transplantability rate of HCC was 100% before resection, dropped to 75% when a recurrence occurred, and ultimately the actual transplantability following recurrence was even lower at 48%. This large discrepancy between theoretical and actual transplantability following HCC recurrence has also been observed in other series, with the first varying between 25% and 83%, whereas the second ranges between 3% and 49% (Supporting Table S1 (2,5,12-33) ). When an individual patient accepts to enroll in the SLT strategy, he or she accepts the following risks: (1) postoperative mortality following primary liver resection; (2) postoperative irreversible liver failure needing urgent rescue LT; (3) nontransplantability in case of HCC recurrence; (4) high dropout rate whenever listed for HCC recurrence; (5) postoperative mortality following SLT; and (6) recurrence following SLT, the main long-term survival determinant. The rates for the above in our study were 5%, 2%, 25%, 36%, 3%, and 27% respectively (Fig. 1) . These six risks underline the need to balance the ratio of "the risks for the patient to the benefits for the society."
In an attempt to optimize this ratio, independent predictors of successful SLT strategy were identified for the first time among those factors available before initial liver resection to enable an estimation of the potential success of this strategy before resection. This was in contrast to most other previous studies where predictors of nontransplantability of HCC recurrence were identified based on histopathological examination of the primary resection specimen and the characteristics of the recurrence, and hence could not guide preresection treatment decisions. (12, 18, 31) In our study, a MELD score >10, and absence of preresection TACE at enrollment in the strategy, emerged as independent predictors of a successful SLT strategy. Preresection TACE in patients with R&T HCC has been reported to increase dropout from definitive surgery attributed to disease progression and liver failure. (40) The small sample size of patients treated with TACE before primary resection in the present series precluded any valuable analysis. In several studies, it was demonstrated that higher MELD scores were related to significant survival benefit after LT, reflecting effective clinical decision taking and recipient selection. (41, 42) Most probably, this is also true for our study, in which higher MELD score independently predicted successful SLT strategy. Adding perioperative and histopathological factors to our multivariate analysis enables "dynamic" patient selection and patient tailored treatment. The identification of posthepatectomy morbidity as an independent predictor of failure of the SLT strategy is in line with the reported independent correlation between postoperative complications after curative resection for HCC and poor OS. (43) A lower T-stage at histopathological examination of the resection specimen is a logical factor, because it reflects smaller disease burden.
It is noteworthy that combined preoperative CT and MRI imaging did not always correspond to histopathological results regarding determination of transplantability before resection according to the Milan criteria. Whereas the whole study population, by definition, met the Milan criteria upon preresection imaging, the resection specimen analysis revealed that 72% of patients (79 of 110) still met these criteria, whereas 31 (28%) did not anymore (mainly because of larger tumor diameter and macroscopic subsegmental PVTT).
So far, cumulative mortality rates of primary liver resection and SLT have never been directly reported and could only be calculated in 7 of 23 studies, varying between 1% and 7% (Supporting Table S1 (2, 5, ). This cumulative postoperative mortality (6.4% of patients in our study) is important information that needs to be shared with the potential candidate for the SLT strategy. (7) Most of the previous studies have focused on outcomes from the time of SLT rather than on an ITT basis (from the time of initial resection). In our series, 5-year OS after SLT was 85%, comparing favorably with most of the published series. (9, 10, 12, 44, 45) Repeated curative treatments, including liver resection and local ablative techniques, are an important factor in achieving these favorable long-term outcomes. The post-SLT recurrence rate was 27% in our series, which lies within the spectrum reported in relevant series of SLT for HCC. (46) Several studies comparing the SLT strategy with primary LT, of whom only a few used an ITT design, showed that (1) only 32.5% (range, 22-49) of patients with tumor recurrence after primary resection ultimately were transplanted; (2) OS rates after SLT did not significantly differ from those after primary LT, however, noninferiority could not be proven; and (3) 5-year DFS rates were worse after completed SLT. (16, 19, 47, 48) Furthermore, whereas these studies included many patients exceeding the Milan criteria at primary resection, our study population consisted only of patients fulfilling these criteria, reinforcing our message.
Based on our results, the SLT strategy should be considered with extreme caution, or even contraindicated, in patients in whom both negative preoperative predictors are present. In these patients, we would rather consider upfront listing for primary LT and neoadjuvant pretransplant ablation therapy, such as TACE, radiofrequency, or bridge resection, to control the disease during the waiting period. When a suitable healthy living liver donor is available, living donor liver transplantation (LDLT) should be preferred. Our group has recently shown, on an ITT basis, that LDLT eliminates the waiting period and yields favorable long-term outcomes in HCC patients. (49) When no negative preoperative factors are present, the patient should be encouraged to enroll in the SLT strategy after informing him or her (1) about the risks and possible long-term outcomes and (2) that this might be revised (maintained or changed) after primary resection in case of postoperative complications, and according to the histopathological results of the resection specimen.
Our study does have some shortcomings. First, it is a retrospective analysis of prospectively collected data over a long period of time, during which the accuracy of imaging modalities, ease of access to LT, and perioperative management have improved. However, the SLT strategy has been applied at our center to all consecutive eligible patients already since 1990, (13) and our study population is possibly one of the largest singlecenter series of SLT patients to date. Second, randomized-controlled trials, on an ITT basis, comparing the SLT strategy with other strategies, such as upfront LT or resection as a bridge to LT, would be ideal. However, such trials may not be possible because of practical and ethical reasons, as well as the possibilities provided by LDLT. Third, some events following primary resection have been classified as SLT strategy failures (e.g., development of extrahepatic metastases), whereas these actually are not strategy failures (e.g., primary resection obviated upfront LT, which would have been followed by extrahepatic metastases). The choice to classify these cases as SLT strategy failures was guided by our main study objective, that is, performing an analysis in the patient's perspective and perception of cure. (7) In conclusion, the low actual transplantability rate after HCC recurrence following primary resection remains the Achilles heel of the SLT strategy. The best candidates for this strategy are patients with a higher MELD score, no preoperative TACE, no postoperative complications after initial resection, and low T-stage in the resected specimen. These predictive factors enable patient-tailored health care in HCC patients by selecting best candidates for the SLT strategy, still saving liver grafts. The results of our study should facilitate both an upstream and a dynamic shared-decision process between doctors and a wellinformed patient to enroll or not in the SLT strategy.
